| Hypertensive disease

CaroSpir vs Katerzia

Side-by-side clinical, coverage, and cost comparison for hypertensive disease.

Deep comparison between: Carospir vs Katerzia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKaterzia has a higher rate of injection site reactions vs Carospir based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Katerzia but not Carospir, including UnitedHealthcare

Category

Carospir

Katerzia

At A Glance

RouteOral

FrequencyDaily

ClassAldosterone antagonist

RouteOral

FrequencyDaily

ClassCalcium channel blocker

Indications

Heart failure with reduced ejection fraction
Hypertensive disease
Edema

Hypertensive disease
Stable angina
Angina Pectoris, Variant
Coronary Artery Disease

Dosing

Heart failure with reduced ejection fraction Initiate at 20 mg once daily; may increase to 37.5 mg once daily as clinically indicated; may reduce to 20 mg every other day if hyperkalemia develops; consider initiating at 10 mg once daily in patients with eGFR 30-50 mL/min/1.73m2.

Hypertensive disease Initiate at 20 to 75 mg daily in single or divided doses; titrate at two-week intervals; doses >75 mg/day generally do not provide additional blood pressure reduction.

Edema Initiate in a hospital setting at 75 mg daily in single or divided doses; titrate slowly; administer for at least five days before increasing dose to obtain desired effect.

Hypertensive disease (adults) 5 mg orally once daily (max 10 mg); start 2.5 mg in small, fragile, elderly patients, or those with hepatic insufficiency.

Hypertensive disease (pediatric, ages 6-17) 2.5-5 mg orally once daily; doses >5 mg have not been studied in pediatric patients.

Stable angina, Angina Pectoris, Variant 5-10 mg orally once daily; lower dose suggested in elderly and patients with hepatic insufficiency; most patients require 10 mg.

Coronary Artery Disease 5-10 mg orally once daily; majority of patients required 10 mg in clinical studies.

Contraindications

Hyperkalemia
Addison's disease
Concomitant use of eplerenone

Known sensitivity to amlodipine

Drug Interactions

1197View drug interactions

1162View drug interactions

Adverse Reactions

Serious Hyperkalemia, hypotension, worsening renal function, electrolyte and metabolic abnormalities, gynecomastia, impaired neurological function or coma in patients with hepatic impairment and cirrhosis with ascites

Postmarketing Gastric bleeding, ulceration, gastritis, nausea, vomiting, diarrhea, gynecomastia, decreased libido, erectile dysfunction, irregular menses, amenorrhea, postmenopausal bleeding, leukopenia, agranulocytosis, thrombocytopenia, fever, urticaria, anaphylactic reactions, vasculitis, hyponatremia, hypovolemia, leg cramps, lethargy, mental confusion, ataxia, dizziness, headache, renal dysfunction, renal failure, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS, alopecia, pruritus, chloasma, cholestatic/hepatocellular toxicity

Most common (>1%) edema, dizziness, flushing, palpitation, fatigue, nausea, abdominal pain, somnolence

Postmarketing gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder

Pharmacology

Aldosterone antagonist; spironolactone and its active metabolites competitively bind aldosterone receptors at the sodium-potassium exchange site in the distal convoluted renal tubule, increasing sodium and water excretion while retaining potassium, exerting diuretic and antihypertensive effects.

Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation, reduction in peripheral vascular resistance, and reduction in blood pressure.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Carospir